Sugi Predict

Sugi Predict / Targets / RET

RET

Proto-oncogene tyrosine-protein kinase receptor Ret · P07949 · RET on Sugi Atlas →

328,978 patent compounds predicted against RET, 219,362 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL19816 SCHEMBL19816 1.00 11/20
SCHEMBL19817 SCHEMBL19817 1.00 11/20
SCHEMBL19978 SCHEMBL19978 1.00 10/20
SCHEMBL19979 SCHEMBL19979 1.00 10/20
SCHEMBL8684 SCHEMBL8684 0.66 10/20
SCHEMBL20228 SCHEMBL20228 0.64 10/20
SCHEMBL20229 SCHEMBL20229 0.64 10/20
SCHEMBL25446 SCHEMBL25446 0.57 9/20
SCHEMBL20419 SCHEMBL20419 0.57 9/20
SCHEMBL20420 SCHEMBL20420 0.57 9/20
SCHEMBL19725 SCHEMBL19725 0.58 8/20
SCHEMBL19726 SCHEMBL19726 0.58 8/20
SCHEMBL21719 SCHEMBL21719 0.57 8/20
SCHEMBL21720 SCHEMBL21720 0.57 8/20
SCHEMBL19896 SCHEMBL19896 0.52 8/20
SCHEMBL26261 SCHEMBL26261 0.47 8/20
Semaxanib Semaxanib (SCHEMBL19571) 1.00 7/20
Semaxanib Semaxanib (SCHEMBL19572) 1.00 7/20
SCHEMBL9478 SCHEMBL9478 0.77 7/20
SCHEMBL31292 SCHEMBL31292 0.49 7/20

Clinical trials — most relevant to RET by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
A Study Comparing TAK-928 With Docetaxel in Adults With Non-Small Cell Lung Cancer PHASE3RECRUITING
A Study of Pralsetinib Versus Standard of Care (SOC) for Treatment of RET-Mutated Medullary Thyroid Cancer (MTC). PHASE3WITHDRAWN
Phase 3 Study of Sitravatinib Plus Nivolumab vs Docetaxel in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer PHASE3COMPLETED
Cabozantinib Plus Docetaxel and Prednisone for Advanced Prostate Cancer PHASE1/PHASE2COMPLETED
A Trial Evaluating the Activity and Safety of Combination Between Cabozantinib and Temozolomide in Lung and GEP-NENS Progressive After Everolimus, Sunitinib or PRRT (CABOTEM) PHASE2RECRUITING
Neoadjuvant Combination Therapy of Lenvatinib and TACE for Transplant-Eligible Large Hepatocellular Carcinoma Patients PHASE2ENROLLING_BY_INVITATION
Restor. I-131 Upt. + Selpercatinib in RET F-P RAI-R TC PHASE2RECRUITING
A Study to Evaluate Foretinib in Subjects With Non-Small-Cell Lung Cancer PHASE2WITHDRAWN
Fulvestrant +/- Vandetanib in Advanced Aromatase Inhibitor Resistant Breast Cancer PHASE2UNKNOWN
Phase II Study of Single Agent Lenvatinib PHASE2UNKNOWN
A Study Evaluating the Activity of Anti-cancer Treatments Targeting Tumor Molecular Alterations/Characteristics in Advanced / Metastatic Tumors. PHASE2RECRUITING
A Phase 2 Study of Anvumetostat in Participants With MTAP-deleted Advanced NSCLC (MTAPESTRY 201) PHASE2ACTIVE_NOT_RECRUITING
Study of RET Inhibitor TAS0953/HM06 in Patients With Advanced Solid Tumors With RET Gene Abnormalities PHASE1/PHASE2RECRUITING
A Study of Sunitinib Versus Placebo in Combination With Lanreotide in Patients With Progressive Advanced/Metastatic Midgut Carcinoid Tumors PHASE2UNKNOWN
Study of ST-1898 in Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Cancer PHASE2RECRUITING
Vandetanib to Treat Children and Adolescents With Medullary Thyroid Cancer PHASE1/PHASE2COMPLETED
Pembrolizumab With Sitravatinib in Recurrent Endometrial Cancer and Other Solid Tumors With Deficient Mismatch Repair System PHASE2WITHDRAWN
AUY922 in Patient With Stage IV NSCLC PHASE2COMPLETED
A Study of Tepotinib and Ivonescimab in People With Non-Small Cell Lung Cancer PHASE1RECRUITING
Study of RXDX-105, Potent RET Inhibitor in Patients With Advanced Lung Cancer and Other Solid Tumors PHASE1COMPLETED
Toripalimab Combined With Anlotinib and SBRT in Patients With Untreated Brain Metastases of Driven Gene-negative NSCLC PHASE1COMPLETED
Molecular Profile of Metastatic Sporadic Medullary Thyroid Cancer Patients and Correlation With Vandetanib nanCOMPLETED
Natural History Study of Children and Adults With Medullary Thyroid Cancer nanRECRUITING
A Taiwanese Oncogenetic Panel and Integrated Clinical Data Registry Study for Advanced Thyroid Cancer Patients (TOPICS-THYROID) nanACTIVE_NOT_RECRUITING
Expanded Access to RXDX-105 for Cancers With RET Alterations nanNO_LONGER_AVAILABLE
Pan-Canadian Lung Cancer Observational Study (PALEOS) nanRECRUITING
Clinical and Molecular Study With Digital Support of Patients With Inoperable Lung Cancer nanCOMPLETED
Expanded Access for LOXO-260 in Participants With Cancer Caused by an Abnormal RET Gene That Did Not Respond/is no Longer Responding to Treatment With a Type of Drug Called a RET Inhibitor nanNO_LONGER_AVAILABLE
RET Inhibitor for Neoadjuvant Therapy in Locally Advanced RET-altered Thyroid Cancer nanRECRUITING
HAIC Plus Lenva and PD-1 for Advanced HCC With Macrovascular or Biliary Invasion nanACTIVE_NOT_RECRUITING

Related proteins — ESM-2 sequence neighbours (a RET binder may also engage these)

ProteinNameSimilarity
Q00495 — 1.000 Q00495 →
P35546 — 1.000 P35546 →
CSF1R Macrophage colony-stimulating factor 1 receptor 1.000 landscape →
P13369 — 1.000 P13369 →
G3V9H8 — 0.999 G3V9H8 →
Q28889 — 0.997 Q28889 →
P79750 — 0.997 P79750 →
Q09147 — 0.996 Q09147 →
Q91ZT1 — 0.996 Q91ZT1 →
Q2HWD6 — 0.996 Q2HWD6 →
EPHA5 Ephrin type-A receptor 5 0.995 landscape →
Q76II0 — 0.995 Q76II0 →
Q28317 — 0.995 Q28317 →
O09127 — 0.995 O09127 →
MUSK Muscle, skeletal receptor tyrosine-protein kinase 0.994 landscape →
B6ZK77 — 0.994 B6ZK77 →
P14617 — 0.994 P14617 →
Q8AXC6 — 0.994 Q8AXC6 →
P05532 — 0.994 P05532 →
Q91909 — 0.993 Q91909 →
Q91735 — 0.993 Q91735 →
Q8AXC7 — 0.993 Q8AXC7 →
P54758 — 0.993 P54758 →
B4HY03 — 0.992 B4HY03 →
B1AUH1 — 0.992 B1AUH1 →
Q03146 — 0.992 Q03146 →
Q05030 — 0.992 Q05030 →
EPHB4 Ephrin type-B receptor 4 0.992 landscape →
Q8K337 — 0.992 Q8K337 →
Q9DE49 — 0.992 Q9DE49 →